Abstract:Fearnley et al reported an ataxia case with a 46 of 29 CAG repeats in THAP11, comorbid with a 22-CAG repeat expansion in CACNA1A from European-ancestry ataxia cohort. This patient was diagnosed as hereditary ataxia at the age of 40 and Parkinson's disease at 53. The comorbidity of two polyglutamine (polyQ) diseases may complicate the phenotype and further assessment is warranted. Nevertheless, this is the first time that CAG expansion greater than 45 repeats in THAP11 was found beyond Chinese ataxia population. Therefore, this patient further confirmed this new subtype of spinocerebellar ataxia (SCA). In addition, Fearnley et al also investigated the normal expansion ranging from 19 to 39 repeats in THAP11 from 2504 individuals in 1000 Genomes. In general, these findings suggest that ATX-THAP11 is not limited to Asian. As the latest SCA included in Online Mendelian Inheritance in Man (OMIM) is SCA50, the new SCA subtype caused by the CAG expansion in THAP11 identified by us is appropriately named ATX-THAP11/SCA51. The pathogenic mechanism of polyQ diseases is widely attributed to the toxicity of abnormal proteins containing stretches of polyQ residues.1 We observed an increase in the length of glutamine correlates with a more severe phenotype in our ATX-THAP11/SCA51 family.2 Interestingly, expansion of CAG repeats interrupted by CAA is common in polyQ disease, which encodes the same glutamine for polyQ stretch, but may lead to distinct RNA secondary structures.1 In recent years, several reports have explored the impact of various DNA structures within CAG repeats on the severity of polyQ diseases. Three independent studies have reported that in individuals with Huntington's disease (HD), a reduction in CAA insertions and an increase in uninterrupted CAG repeats are associated with an earlier onset age of HD.3, 4 Conversely, increased CAA insertions are linked to delayed disease onset.3 Further comparisons among different HD mouse models have demonstrated that longer uninterrupted CAG repeats are associated with striatum-selective transcriptionopathy, possibly because of CAG repeat instability and nuclear aggregation.5 Another intriguing observation is that pure CAG repeats in ATXN2 are associated with SCA2, whereas CAG repeats in ATXN2 causing amyotrophic lateral sclerosis (ALS) and Parkinson's disease are predominantly interrupted by CAA.6 In Drosophila models, ataxin-2 encoded by pure CAG repeats induces retinal and neurotoxicity, whereas CAA insertions or only CAA repeats do not induce toxicity, despite producing the same protein.7 In our large family affected by ATX-THAP11/SCA51, we noted a decrease in CAA insertions and an increase in pure CAG length. However, there was no decrease in CAA insertions in our other family or in the patient reported by Fearnley et al. Currently, because of the limited number of ATX-THAP11/SCA51 patients, whether CAA interruption modulates pathogenesis of polyQ aggregation and influences clinical phenotypes needs further exploration. In the future, it is necessary to detect CAG repeat expansion of THAP11 across ethnically and geographically different ataxia populations to clarify its genotype–phenotype characteristics and pathogenesis of ATX-THAP11/SCA51. The author declares that the research was conducted in the absence of other commercial or financial relationships that could be construed as a potential conflict of interest. (1) Research project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript: A. Writing of the First Draft, B. Review and Critique. H.X., H.J., and N.Z. contributed to the conception and design of the study, as well as reviewed the draft; D.T., W.J., and Z.C. contributed to the analysis of data and drafting of the text. Not applicable.

Study of Intermediate-Length polyQ Repeats in Sporadic and Familial Amyotrophic Lateral Sclerosis

Intermediate-length Polyglutamine in ATXN2 is a Possible Risk Factor among Eastern Chinese Patients with Amyotrophic Lateral Sclerosis

ATXN 2 CAG Repeat Expansions Increase the Risk for Chinese Patients with Amyotrophic Lateral Sclerosis

Intermediate Repeat Expansion in the ATXN2 Gene as a Risk Factor in the ALS and FTD Spanish Population

The Repeat Length of C9orf72 is Associated with the Survival of Amyotrophic Lateral Sclerosis Patients Without C9orf72 Pathological Expansions

[Genetic and Clinical Analysis in a Parkinson's Disease Family Caused by Expansion of SCA2].

Atypical Electropherogram Patterns are Observed Among C9orf72 (G4C2) Expansion Carriers in a Familial and Sporadic ALS and ALS/FTD North American Cohort Study (P5.056)

Identification of GGC Repeat Expansion in the NOTCH2NLC Gene in Amyotrophic Lateral Sclerosis

Intermediate-Length GGC Repeat Expansion in NOTCH2NLC Was Identified in Chinese Patients with Amyotrophic Lateral Sclerosis

ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes

Investigating Repeat Expansions in NIPA1, NOP56, and NOTCH2NLC Genes: A Closer Look at Amyotrophic Lateral Sclerosis Patients from Southern Italy

Reply To: "THAP11 CAG Expansion Beyond Chinese-Ancestry Cohorts: an Examination of 1000 Genomes and UK Biobank"

Whole Exome Sequencing of Familial ALS and Trios of Sporadic ALS to Identify New Genes Associated with ALS (P5.047)

Interplay of Repeat Expansion Genes in Spinocerebellar Ataxia Type 3 (P5.079)

Short tandem repeat expansions in LRP12 are absent in cohorts of familial and sporadic amyotrophic lateral sclerosis patients of European ancestry

Analysis of Chromosome 9 Open Reading Frame 72 Intermediate Hexanucleotide Repeat Expansions in Familial Amyotrophic Lateral Sclerosis Population from Mainland China

Analysis of (CAG)n expansion in ATXN1, ATXN2 and ATXN3 in Chinese patients with multiple system atrophy

Cerebellar C9ran Proteins Associate with Clinical and Neuropathological Characteristics of C9ORF72 Repeat Expansion Carriers

ATTCT and ATTCC repeat expansions in the ATXN10 gene affect disease penetrance of spinocerebellar ataxia type 10

Mutation Screening of ATXN1, ATXN2, and ATXN3 in Amyotrophic Lateral Sclerosis

Genetic Spectrum and Variability in Chinese Patients with Amyotrophic Lateral Sclerosis.